Investigation of Enzyme (β-Glucosidase) Inhibitor Obtained from Marine Biofilm Bacteria


Kaçar A., Pazi I., Avunduk S., Omuzbuken B.

International Congress of Engineering and Natural Sciences Studies (ICENSS), Ankara, Türkiye, 7 - 09 Mayıs 2021, ss.37

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Ankara
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.37
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Recently, drug explorations have focused on the structure of products derived from marine natural sources. Glucosidase (enzyme) inhibitors are also among the current research areas in the pharmaceutical industry. The potential uses of marine natural products as sources of chemical compounds for various glucosidase inhibitors are being investigated. Bacteria, in aquatic environments, play a role in various biogeochemical cycles and have important functions in nutrient/energy transport. Biofilm bacteria are an important group, which researched in marine ecosystems. Our study focused on the determination of enzyme (β-glucosidase) inhibitor production by marine biofilm bacteria and the identification of the chemical profile of the obtained extract. For this purpose, the enzyme-agar plate method was used to investigate eight biofilm bacteria (Exiguobacterium homiense FJ200652, Vibrio lentus FJ200648, Alteromonas genoviensis FJ200641, Pseudoalteromonas agarivorans FJ040187, Pseudoalteromonas haloplanktis FJ040185, Pseudoalteromonas elyakovii FJ200649, Pseudoalteromonas porphyrae FJ200650, Pseudoalteromonas marina FJ200653) and the inhibition tests of the methanol extracts were performed. As a result of the research, we found that the biofilm bacteria have the potential to produce β-glucosidase inhibitors. It was determined that the extracts of five bacteria contain inhibitors. In addition, according to chemical profiling analyzes, it was revealed that Pseudoalteromonas elyakovii FJ200649 has total flavonoid (17.081%), alkaloid (3.379%), phenolic (8.187%), and terpenoid (0.457%) contents. As a result, advanced structural analysis of this enzyme inhibitor will be performed to investigate its active pharmaceutical use potential.